SG11201909290TA - Assay to measure the potency of receptor-ligand interactions in nanomedicines - Google Patents
Assay to measure the potency of receptor-ligand interactions in nanomedicinesInfo
- Publication number
- SG11201909290TA SG11201909290TA SG11201909290TA SG11201909290TA SG 11201909290T A SG11201909290T A SG 11201909290TA SG 11201909290T A SG11201909290T A SG 11201909290TA SG 11201909290T A SG11201909290T A SG 11201909290TA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- pmhc
- per
- potency
- assay
- Prior art date
Links
- 238000003556 assay Methods 0.000 title abstract 3
- 230000003993 interaction Effects 0.000 title abstract 2
- 239000003446 ligand Substances 0.000 title abstract 2
- 108091008874 T cell receptors Proteins 0.000 abstract 3
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 abstract 3
- 210000004027 cell Anatomy 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 241000754798 Calophyllum brasiliense Species 0.000 abstract 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000006870 function Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000002105 nanoparticle Substances 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 230000037361 pathway Effects 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56977—HLA or MHC typing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/605—MHC molecules or ligands thereof
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/902—Oxidoreductases (1.)
- G01N2333/90241—Oxidoreductases (1.) acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Toxicology (AREA)
- Wood Science & Technology (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Mycology (AREA)
- Rheumatology (AREA)
- Nanotechnology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762483298P | 2017-04-07 | 2017-04-07 | |
| PCT/IB2018/000510 WO2018185564A2 (fr) | 2017-04-07 | 2018-04-05 | Dosage pour mesurer la puissance d'interactions ligand-récepteur dans des nanomédicaments |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201909290TA true SG11201909290TA (en) | 2019-11-28 |
Family
ID=63713282
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201909290T SG11201909290TA (en) | 2017-04-07 | 2018-04-05 | Assay to measure the potency of receptor-ligand interactions in nanomedicines |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20200057048A1 (fr) |
| EP (1) | EP3607058A4 (fr) |
| JP (2) | JP2020516594A (fr) |
| KR (1) | KR20200004807A (fr) |
| CN (1) | CN110945120A (fr) |
| AU (1) | AU2018248961B2 (fr) |
| BR (1) | BR112019021022A2 (fr) |
| CA (1) | CA3059016A1 (fr) |
| CO (1) | CO2019011018A2 (fr) |
| IL (1) | IL269846A (fr) |
| MX (1) | MX2019012058A (fr) |
| RU (1) | RU2019135533A (fr) |
| SG (1) | SG11201909290TA (fr) |
| WO (1) | WO2018185564A2 (fr) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9511151B2 (en) | 2010-11-12 | 2016-12-06 | Uti Limited Partnership | Compositions and methods for the prevention and treatment of cancer |
| US10988516B2 (en) | 2012-03-26 | 2021-04-27 | Uti Limited Partnership | Methods and compositions for treating inflammation |
| US9603948B2 (en) | 2012-10-11 | 2017-03-28 | Uti Limited Partnership | Methods and compositions for treating multiple sclerosis and related disorders |
| JP2017500285A (ja) | 2013-11-04 | 2017-01-05 | ユーティーアイ リミテッド パートナーシップ | 持続的免疫療法のための方法および組成物 |
| US12011480B2 (en) | 2015-05-06 | 2024-06-18 | Uti Limited Partnership | Nanoparticle compositions for sustained therapy |
| CA3232037A1 (fr) * | 2021-09-21 | 2023-03-30 | Monash University | Methodes de traitement |
| CN113960003B (zh) * | 2021-10-20 | 2023-10-24 | 吉林大学 | 基于dna银纳米簇和金纳米棒检测四环素的适配体传感器 |
| US11873507B2 (en) | 2021-11-29 | 2024-01-16 | Replicate Bioscience, Inc. | Compositions and methods for expression of IL-12 and IL-1RA |
| EP4249062A1 (fr) * | 2022-03-24 | 2023-09-27 | Julius-Maximilians-Universität Würzburg | Immunosuppression spécifique de l'aquaporine 4 (aqp4) médiée par mhc ib en tant que nouveau traitement pour la nmo |
| CN115125205A (zh) * | 2022-06-14 | 2022-09-30 | 中国医学科学院生物医学工程研究所 | 一种修饰EpCAM抗体和/或CSV抗体的白细胞磁球及其制备方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0417954D0 (en) * | 2004-08-12 | 2004-09-15 | Avidex Ltd | Cellulat TCR ligand assay method |
| CN101678090B (zh) * | 2007-03-07 | 2012-04-11 | 乌第有限合伙公司 | 用于预防和治疗自身免疫病的组合物和方法 |
| US8809057B2 (en) * | 2012-01-04 | 2014-08-19 | Raytheon Bbn Technologies Corp. | Methods of evaluating gene expression levels |
| JP6891112B2 (ja) * | 2014-11-20 | 2021-06-18 | プロメガ コーポレイションＰｒｏｍｅｇａ Ｃｏｒｐｏｒａｔｉｏｎ | 免疫チェックポイントの調節因子を評価するためのシステム及び方法 |
| AU2015366305B2 (en) * | 2014-12-19 | 2020-03-05 | ETH Zürich | Chimeric antigen receptors and methods of use |
| EP3067366A1 (fr) * | 2015-03-13 | 2016-09-14 | Max-Delbrück-Centrum Für Molekulare Medizin | Thérapie génique liée au récepteur de lymphocytes T combinés du cancer contre des épitopes restreints au CMH classe I ou classe I de l'antigène tumoral NY-ESO-1 |
| IL302341A (en) * | 2015-03-27 | 2023-06-01 | Harvard College | Modified T cells and methods for their preparation and use |
| US12011480B2 (en) * | 2015-05-06 | 2024-06-18 | Uti Limited Partnership | Nanoparticle compositions for sustained therapy |
| US10858760B2 (en) * | 2015-06-01 | 2020-12-08 | Medigene Immunotherapies Gmbh | T cell receptor library |
| MA44907A (fr) * | 2015-09-11 | 2018-07-18 | Agenus Inc | Cellules hôtes génétiquement modifiées et leurs procédés d'utilisation |
-
2018
- 2018-04-05 BR BR112019021022A patent/BR112019021022A2/pt not_active Application Discontinuation
- 2018-04-05 KR KR1020197032951A patent/KR20200004807A/ko unknown
- 2018-04-05 CN CN201880038292.4A patent/CN110945120A/zh active Pending
- 2018-04-05 RU RU2019135533A patent/RU2019135533A/ru not_active Application Discontinuation
- 2018-04-05 EP EP18781139.3A patent/EP3607058A4/fr active Pending
- 2018-04-05 CA CA3059016A patent/CA3059016A1/fr active Pending
- 2018-04-05 MX MX2019012058A patent/MX2019012058A/es unknown
- 2018-04-05 SG SG11201909290T patent/SG11201909290TA/en unknown
- 2018-04-05 JP JP2019554417A patent/JP2020516594A/ja active Pending
- 2018-04-05 US US16/603,180 patent/US20200057048A1/en not_active Abandoned
- 2018-04-05 WO PCT/IB2018/000510 patent/WO2018185564A2/fr active Application Filing
- 2018-04-05 AU AU2018248961A patent/AU2018248961B2/en active Active
-
2019
- 2019-10-04 CO CONC2019/0011018A patent/CO2019011018A2/es unknown
- 2019-10-06 IL IL26984619A patent/IL269846A/en unknown
-
2023
- 2023-09-01 US US18/459,960 patent/US20240201171A1/en active Pending
-
2024
- 2024-02-21 JP JP2024024899A patent/JP2024073459A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| RU2019135533A (ru) | 2021-05-07 |
| EP3607058A2 (fr) | 2020-02-12 |
| EP3607058A4 (fr) | 2020-12-16 |
| US20240201171A1 (en) | 2024-06-20 |
| WO2018185564A3 (fr) | 2019-01-03 |
| AU2018248961B2 (en) | 2024-06-20 |
| KR20200004807A (ko) | 2020-01-14 |
| WO2018185564A2 (fr) | 2018-10-11 |
| IL269846A (en) | 2019-11-28 |
| CA3059016A1 (fr) | 2018-10-11 |
| US20200057048A1 (en) | 2020-02-20 |
| JP2020516594A (ja) | 2020-06-11 |
| AU2018248961A1 (en) | 2019-10-31 |
| BR112019021022A2 (pt) | 2020-06-09 |
| CN110945120A (zh) | 2020-03-31 |
| CO2019011018A2 (es) | 2019-10-21 |
| MX2019012058A (es) | 2019-11-11 |
| JP2024073459A (ja) | 2024-05-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201909290TA (en) | Assay to measure the potency of receptor-ligand interactions in nanomedicines | |
| SG11201808797XA (en) | T cell receptors | |
| SG11201908336XA (en) | Smart plans | |
| SG11201908330PA (en) | Farnesoid x receptor agonists and uses thereof | |
| SG11201809963XA (en) | Application framework using blockchain-based asset ownership | |
| SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof | |
| SG11201904942YA (en) | Blockchain-based service execution method and apparatus, and electronic device | |
| SG11201908719QA (en) | Biomarkers and car t cell therapies with enhanced efficacy | |
| SG11201909344SA (en) | Anti-lag3 antibodies | |
| SG11201810887UA (en) | Baff-r targeted chimeric antigen receptor-modified t-cells and uses thereof | |
| SG11201907870VA (en) | Compositions and methods for inhibition of lineage specific proteins | |
| SG11201808196UA (en) | Neoantigens and methods of their use | |
| SG11201908090VA (en) | Biomonitoring devices, methods, and systems for use in a bathroom setting | |
| SG11201908796XA (en) | Improved antigen binding receptors | |
| SG11201806496SA (en) | Antigen binding proteins that bind pd-l1 | |
| SG11201809584XA (en) | A method and system for verifying ownership of a digital asset using a distributed hash table and a peer-to-peer distributed ledger | |
| SG11201908756SA (en) | System and method for distributing data records using a blockchain | |
| SG11201804673WA (en) | Novel anti-claudin antibodies and methods of use | |
| SG11201907650RA (en) | Personal therapy and exercise monitoring and oversight devices, systems, and related methods | |
| SG11201907023UA (en) | Method of reducing neutropenia | |
| SG11201908784TA (en) | Improved antigen binding receptor formats | |
| SG11201810525XA (en) | Anti-gitr antibodies and uses thereof | |
| SG11201908238SA (en) | Anti-c5 antibodies and uses thereof | |
| SG11201903737PA (en) | Neutralizing anti-tl1a monoclonal antibodies | |
| SG11201806133UA (en) | Intermediates in the synthesis of eribulin and related methods of synthesis |